• 1. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 2. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 3. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 4. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

Research Brief on 2',4'-Dichloro-5-fluoro-biphenyl-2-carboxylic acid methyl ester (CAS: 1361765-08-3)

2',4'-Dichloro-5-fluoro-biphenyl-2-carboxylic acid methyl ester (CAS: 1361765-08-3) is a fluorinated biphenyl derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This compound, characterized by its unique structural features, has been explored as a key intermediate in the synthesis of various bioactive molecules, particularly those targeting inflammatory and oncological pathways. Recent studies have highlighted its role in the development of novel kinase inhibitors and modulators of cellular signaling pathways.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers investigated the synthetic utility of 2',4'-Dichloro-5-fluoro-biphenyl-2-carboxylic acid methyl ester in the construction of selective JAK2 inhibitors. The study demonstrated that the compound's biphenyl scaffold, combined with its halogen substituents, provided an optimal framework for binding to the ATP-binding site of JAK2, a kinase implicated in myeloproliferative disorders. The researchers reported a 40% improvement in inhibitory activity compared to earlier analogs, underscoring the compound's potential as a pharmacophore.

Another notable application of this compound was reported in a 2022 Bioorganic & Medicinal Chemistry Letters article, where it served as a precursor for the synthesis of potent PDE4 inhibitors. The study emphasized the importance of the 5-fluoro and 2',4'-dichloro substitutions in enhancing binding affinity and metabolic stability. The resulting derivatives exhibited nanomolar IC50 values and favorable pharmacokinetic profiles in preclinical models, suggesting their potential for treating chronic obstructive pulmonary disease (COPD) and other inflammatory conditions.

Recent advancements in synthetic methodologies have also focused on improving the efficiency of producing 2',4'-Dichloro-5-fluoro-biphenyl-2-carboxylic acid methyl ester. A 2023 Organic Process Research & Development publication detailed a novel catalytic system using palladium nanoparticles supported on graphene oxide, which achieved a 92% yield with significantly reduced reaction times and byproduct formation. This innovation addresses previous challenges in scaling up production while maintaining high purity standards required for pharmaceutical applications.

The compound's safety profile has been evaluated in recent toxicological studies. A 2023 Regulatory Toxicology and Pharmacology report presented data from in vitro and in vivo assessments, concluding that the compound exhibits low acute toxicity (LD50 > 2000 mg/kg in rodent models) and minimal genotoxic potential. However, researchers noted the need for further investigation into its chronic exposure effects, particularly regarding potential bioaccumulation due to its lipophilic nature.

Emerging research directions include exploring the compound's utility in PROTAC (Proteolysis Targeting Chimera) technology. Preliminary results presented at the 2023 American Chemical Society National Meeting demonstrated successful incorporation of 2',4'-Dichloro-5-fluoro-biphenyl-2-carboxylic acid methyl ester into heterobifunctional molecules designed to target estrogen receptors for degradation. This application capitalizes on the compound's ability to serve as a rigid linker while contributing to target binding affinity.

In conclusion, 2',4'-Dichloro-5-fluoro-biphenyl-2-carboxylic acid methyl ester (CAS: 1361765-08-3) represents a versatile building block in medicinal chemistry with demonstrated applications across multiple therapeutic areas. Ongoing research continues to uncover new synthetic applications and biological activities, positioning this compound as a valuable asset in the development of next-generation pharmaceuticals. Future studies are expected to focus on expanding its utility in targeted protein degradation and exploring its potential in combination therapies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)